Skip to main content

European expertise,
multi-regional reach.

We are one of Europe's leading healthcare companies and rank among the twenty largest manufacturers of generic medicines worldwide. We are privately owned, with ninety years of history, and we bring locally relevant medicines to market through one connected, integrated platform.

founded in

1935, Starogard Gdański

Ownership

Privately held

Headquarters

Warsaw, Poland

FY2025 revenue

€1.2 billion

our purpose and vision

We make medicines people can afford and rely on, for everyday conditions and for the most serious illnesses.

Our Purpose

Helping people to live a healthy life 
in a healthy world.

Affordable care, dependable quality - making the medicines people count on for everyday conditions and the most serious illnesses alike.

THE STARTING POINT
FOR EVERYTHINGTHE GROUP DOES

our vision

A healthcare platform outpacing markets, 
with solutions available to all.

European core, entrepreneurial drive - growing beyond our home markets while keeping medicines within reach of the people who need them.

THE DIRECTION WE ARE
BUILDING TOWARD

Certification by site

Ninety years in business, 
privately owned since 2000.

Private ownership lets us decide quickly and invest on a long horizon. We have compounded revenue at close to 12% a year since 2021, and make roughly three quarters of what we sell at our own sites.

Group revenue, FY2025

€1.2B

Revenue CAGR, 2021–2025

~12%

Employees

6,2k

Manufacturing sites

8

FDF R&D centres

4

API R&D Centers

2

STRUCTURE

A group of specialised competences

In its core regions Polpharma Group sells through its own commercial companies; beyond them, it out-licenses to partners who market the products as their own.

Company
Poland

ZF Polpharma

Poland's leading drug manufacturer and a pillar of the country's pharmaceutical independence.
Manufacturing
POLAND & CEE
Company
Kazakhstan

Polpharma Santo

A leading manufacturer in Kazakhstan since 1882, securing essential medicines across Central Asia.
Manufacturing
POLAND & CEE
Unit
Poland

Polpharma API

European CDMO and Gx manufacturer
with 75 years of experience in supporting patients’ health ​with high quality APIs
API Manufacturing
POLAND & CEE
Unit
Poland

Polpharma CMO

Customised finished-dosage production with full analytical support.
CMO
POLAND & CEE
Company
Spain

Farmaprojects

A single route into Europe: dossier adaptation, regulatory strategy, supply and launch.
Out-Licensing
POLAND & CEE
Company
Germany

089PHARM

Scalable tender platform in Europe's largest pharmaceutical market.
Tenders & Retail Market
POLAND & CEE
Company
Poland

Ziołolek

Over-the-counter medicines, dermo-cosmetics and supplements, with a focus on emollients and everyday skin care.
Consumer Healthcare
POLAND & CEE
Company
Poland

Polfa Lublin

Pharmaceutical packaging, dosing devices and contract manufacturing for international pharma companies.
Packaging & Devices
POLAND & CEE
Previous
Next

HOW THE GROUP OPERATES

The same standards, in every company

We are a family of specialised companies with one operating character and one compliance bar. Our quality, pharmacovigilance and ethics standards apply in every company and every market.

01 Entrepreneurial
We pursue opportunities with discipline and back them with investment. We are measured on results.
02 Scientific
We pursue opportunities with discipline and back them with investment. We are measured on results.
03 Agile
Private ownership lets us decide quickly and adapt to each market.
04 Brave
We take on hard-to-make medicines and complex platforms others avoid, and we plan in decades.
05 Collaborative
We work as partners across the healthcare ecosystem and build relationships for the long term.
06 Focused
We choose where to compete and run a cost-competitive operating model behind it.

intergrated value chain

An integrated pharmaceutical platform, from synthesis to the patient.

You can work with us at one point on the value chain or across all of it. Each capability runs to the same standards and connects to the next, so a partnership in one area has the rest of the platform behind it.

Previous
Next

01 Research

& Development

We develop active substances and finished dosage forms across our own pipeline and with partners - supported by R&D centers across Europe and Central Asia.

6 R&D centers

37 doctorates
€0.5B+ invested since 2000

Research
& Development

02 Active Pharmaceutical
Ingredients

Forty APIs in commercial production, each with a complete DMF stack. From standard chemistry to high-potent compounds, oligonucleotides, and cryogenic synthesis.

65+ patents granted
70+ APIs in portfolio

FDA-approved, EU GMP-certified

Active Pharmaceutical Ingredients

03 Finished Dosage
Forms

Every major form, at scale: solid, sterile, ophthalmic, inhaled, injectables, and more. Four hundred million packs a year, across our own brands and partner programs.

6B tablets

979M capsules

226M ampoules per year

Finished Dosage Forms

04 Commercialisation

& Market Access

Out-licensing and in-licensing programs into hundreds of markets. Own brands across CEE, CIS, Central Asia, and Germany. We lead the categories where we compete.

14+ Markets directly

40+ markets via partners

100+ Markets licenced

Commercialisation
& Market Access

Security of supply

Our leadership team as multi-
regional as the company it runs.

Sebastian Szymanek leads the Group as CEO, with an executive management board and a commercial leadership team responsible for operations, science, finance and the regional businesses. Together they bring decades of pharmaceutical and industrial experience.

See Leadership

At Polpharma, we live our mission: helping people live healthy lives in a healthy world. Success means creating an environment where diverse perspectives meet, where ideas are challenged constructively, and where we learn from each other to achieve extraordinary results. Logic matters, but empathy and trust matter even more.

sebastian szymanek
ceo of polpharma group

From one factory to a multi-regional group

We started in 1935 as a single chemical and pharmaceutical plant in Starogard Gdański. We were nationalised, returned to private Polish ownership in 2000, and have grown through investment and acquisition since: Santo in Kazakhstan, Polfa Warszawa, Farmaprojects in Spain, and most recently Ziołołek.

See the full history
1935
Establishment
A Polish Chemical and Pharmaceutical Plant “Polpharma” was established in Starogard Gdański.
2000
Privatisation
A new chapter in Polpharma's history opened on 20 July. The company became a privately owned entity, with all its shares held by Polish investors. The Spectra Management and Prokom Investments consortium became the majority shareholder. This was the beginning of restructuring and significant investment in the company's development.
2009
FDA approval
Polpharma passed an inspection by the US Food and Drug Administration (FDA). As a result, the active pharmaceutical ingredients manufactured by the company gained access to the highly developed US market.
2011
Santo joins the Group
The largest local drug manufacturer in Kazakhstan - Chimpharm (Santo) - joined Polpharma Group.
2012
Polfa Warszawa acquisition
Polpharma acquired a majority stake in Polfa Warszawa S.A.
2013
Sanfarm acquisition
The company Sanfarm, based in the Tarnobrzeg Special Economic Zone, became part of Polpharma S.A. Pharmaceutical Works. Following the merger, Polpharma's Manufacturing Division in Nowa Dęba was established to carry out pharmaceutical manufacturing for both Polpharma Group companies and third parties.
2021
Farmaprojects acquisition
Acquisition of Farmaprojects S.A.
2022
RNA technology project
Inauguration of a project to implement RNA technology in Poland under the banner “Limitless future of RNA therapeutics” at the Institute of Bioorganic Chemistry of the Polish Academy of Sciences (ICHB PAN) in Poznań. The project is carried out under a Medical Research Agency grant to a consortium of ICHB PAN and Polfa Warszawa, part of Polpharma.
2022
089Pharm GmbH established
Establishment of 089Pharm GmbH.
2024
Ziołolek acquisition
In August 2024, Ziołolek joined Polpharma in Poland, with Polpharma becoming the majority shareholder. Ziołolek manufactures OTC medicines, medical devices, dietary supplements and cosmetics, including emollients for the care of children and infants - expanding Polpharma's portfolio with high-quality dermatological products.
Previous
Next